Two selected reports discuss the tetrapeptide epitalon/AEDG: a mixed animal-and-human retinal report and a human circadian-biomarker report. This is not a review of the distinct pineal extract epithalamin.12
Bottom line from this bounded source set
These reports describe retinal findings and changes in melatonin-related or gene-expression measurements. Their abstracts do not provide enough detail to establish a reliable treatment effect, long-term safety or an effect on human lifespan.12
Reviewed study record
Retinal degeneration: mixed preclinical and clinical report
Design
The publication describes experiments in rats and clinical observations in patients with degenerative retinal lesions.1
Population
The abstract does not state the number of patients or their allocation to a comparator.1
Outcomes reported
The authors reported a positive clinical effect in 90% of cases and retinal effects in rats.1
Limitations
The clinical endpoint, comparator, follow-up and adverse events are insufficiently described in the abstract. The reported percentage is not a controlled effect estimate, and animal findings cannot establish human benefit.1
Reviewed study record
Circadian biomarkers
Design
The report examines AEDG and melatonin-related and clock-gene measurements in people with altered melatonin production.2
Population
The abstract does not give a sufficiently detailed enrollment and allocation account.2
Outcomes reported
The authors reported changes in urinary melatonin metabolite levels and clock-gene expression.2
Limitations
Biomarker changes do not establish better sleep, reduced disease or longer lifespan. Full-text and related-report reconciliation are required to assess design, participant overlap and harms.2